Stabilized protein crystals, formulations comprising them and methods of making them
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C07C-007/14
C07C-007/20
C01C-001/18
출원번호
US-0609650
(2009-10-30)
등록번호
US-8558048
(2013-10-15)
발명자
/ 주소
Margolin, Alexey L.
Khalaf, Nazar K.
St. Clair, Nancy L.
Rakestraw, Scott L.
Shenoy, Bhami C.
출원인 / 주소
Althea Technologies, Inc.
대리인 / 주소
Wilson, Sonsini, Goodrich & Rosati
인용정보
피인용 횟수 :
0인용 특허 :
43
초록▼
This invention relates to methods for the stabilization, storage and delivery of biologically active macromolecules, such as proteins, peptides and nucleic acids. In particular, this invention relates to protein or nucleic acid crystals, formulations and compositions comprising them. Methods are pro
This invention relates to methods for the stabilization, storage and delivery of biologically active macromolecules, such as proteins, peptides and nucleic acids. In particular, this invention relates to protein or nucleic acid crystals, formulations and compositions comprising them. Methods are provided for the crystallization of proteins and nucleic acids and for the preparation of stabilized protein or nucleic acid crystals for use in dry or slurry formulations. The present invention is further directed to encapsulating proteins, glycoproteins, enzymes, antibodies, hormones and peptide crystals or crystal formulations into compositions for biological delivery to humans and animals. According to this invention, protein crystals or crystal formulations are encapsulated within a matrix comprising a polymeric carrier to form a composition. The formulations and compositions enhance preservation of the native biologically active tertiary structure of the proteins and create a reservoir which can slowly release active protein where and when it is needed. Methods are provided preparing stabilized formulations using pharmaceutical ingredients or excipients and optionally encapsulating them in a polymeric carrier to produce compositions and using such protein crystal formulations and compositions for biomedical applications, including delivery of therapeutic proteins and vaccines. Additional uses for-the protein crystal formulations and compositions of this invention involve protein delivery in human food, agricultural feeds, veterinary compositions, diagnostics, cosmetics and personal care compositions.
대표청구항▼
1. A formulation, said formulation comprising: (a) a protein crystal, and(b) at least one excipient selected from the group consisting of sucrose, trehalose, lactitol, gelatin, hydroxypropyl-β-cyclodextrin, and methoxypolyethylene glycol, wherein the amount of methoxypolyethylene glycol in the formu
1. A formulation, said formulation comprising: (a) a protein crystal, and(b) at least one excipient selected from the group consisting of sucrose, trehalose, lactitol, gelatin, hydroxypropyl-β-cyclodextrin, and methoxypolyethylene glycol, wherein the amount of methoxypolyethylene glycol in the formulation does not exceed 30% W/W, and wherein said formulation is characterized by at least a 60 fold greater shelf life when stored at 40° C. to 55° C. than the soluble form of said protein in solution 40° C. to 55° C., as measured by T1/2. 2. The formulation according to claim 1 wherein said protein is a therapeutic protein. 3. A composition for the release of a protein, said composition comprising: (a) a protein crystal formulation, wherein said formulation comprises a protein crystal and at least one excipient selected from the group consisting of sucrose, trehalose, lactitol, gelatin, hydroxypropyl-β-cyclodextrin, and methoxypolyethylene glycol, wherein the amount of methoxypolyethylene glycol in the formulation does not exceed 30% W/W; and(b) at least one polymeric carrier, wherein said formulation is encapsulated within a matrix of said polymeric carrier, and wherein said formulation is characterized by at least a 60 fold greater shelf life when stored at 40° C. to 55° C. than the soluble form of said protein in solution at 40° C. to 55° C., as measured by T1/2. 4. The composition according to claim 3 wherein said protein is a therapeutic protein. 5. The composition according to claim 3 wherein said polymeric carrier is a polymer selected from one or more of the group consisting of poly (acrylic acid), poly (cyanoacrylates), poly (amino acids), poly (anhydrides), poly (depsipeptide), poly (esters), poly (lactic acid), poly (lactic-co-glycolic acid (or PLGA), poly (p-hydroxybutryate), poly (caprolactone), poly (dioxanone); poly (ethylene glycol), poly ((hydroxypropyl) methacrylamide, poly [(organo) phosphazene], poly (ortho esters), poly (vinyl alcohol), poly (vinylpyrrolidone), maleic anhydride alkyl vinyl ether copolymers, pluronic polyols, albumin, alginate, cellulose and cellulose derivatives, collagen, fibrin, gelatin, hyaluronic acid, oligosaccharides, glycaminoglycans, sulfated polysaccharides, blends and copolymers thereof. 6. The formulation according to claim 1, wherein said protein is selected from the group consisting of insulin, amylin, erythropoietin, glucagon-like insulinotropic peptide, Factor VIII, dornase-α α-1-antitripsin, fertility hormones, FSH, LSH, postridical hormones, tetanus toxoid and diphtheria toxoid. 7. The formulation according to claim 1, wherein said protein is an antibody, enzyme, hormone, or glycoprotein.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (43)
Carlson, Andrew David; Sheliga, Theodore Arsay, Activated protein C formulations.
Mateescu Mircea A. (Verdun CAX) Dumoulin Yves (Ste-Julie CAX) Cartilier Louis (Beaconsfield CAX) Lenaerts Vincent (Argenteuil CAX), Cross-linked enzymatically controlled drug release.
Behan John M. (Ashford GB3) Ness Jeremy N. (Canterbury GB3) Perring Keith D. (Ashford GB3), Encapsulating method and products containing encapsulated material.
La Zor Clair G. (13054 Rose St. Cerritos CA 90701), Instrument for locating faults in aircraft passenger reading light and attendant call control system.
McKinnon ; Jr. Charles N. (Laguna Niguel CA) Peterson Steven F. (West Linn OR) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection device.
Peterson Steven F. (West Linn OR) McKinnon ; Jr. Charles N. (Laguna Niguel CA) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection methods and device.
Olson David H. (Pennington NJ) Stucky Galen D. (Santa Barbara CA) Vartuli James C. (West Chester PA), Sensor device containing mesoporous crystalline material.
Gloger Manfred (Weilheim DEX) Heinle Josef (Munich DEX) Schlumberger Helmut (Polling DEX), Soluble liver uricase with a process for the preparation thereof and with the use thereof.
Margolin, Alexey L.; Khalaf, Nazar K.; St. Clair, Nancy L.; Rakestraw, Scott L.; Shenoy, Bhami C., Stabilized protein crystals formulations containing them and methods of making them.
Margolin,Alexey L; Khalaf,Nazar K; St Clair,Nancy L; Rakestraw,Scott L; Shenoy,Bhami C, Stabilized protein crystals, formulations comprising them and methods of making them.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.